Latest Breaking News On - க்வீபெக் அரசு - Page 3 : vimarsana.com

French The shift announced by Quebec will follow a similar approach to policies introduced in British Columbia, Alberta and recently in New Brunswick to transition patients who use a reference biologic to a biosimilar. This will contribute to substantial annual savings that can be reinvested in healthcare and innovative new drugs. The transition will take place under the supervision of the attending physicians and patients will continue receiving safe and effective treatment. Sandoz Canada has a portfolio of six biosimilars (Omnitrope, Rixymio, Erelzi, Hyrimoz, Ziextenzo and Inclunox). Sandoz Canada is committed to supporting patients, their healthcare professionals and the Quebec government throughout the transition period with quality biosimilar medicines, medical teams, physician and pharmacist advocacy teams, as well as proven patient support programs.

United kingdomKarine matteauPaule pelletierMichel robidouxSandoz canada incHealth canada biosimilars fact sheetSandoz international gmbHealth canadaBritish columbiaNew brunswickQuebec governmentSandoz canadaGeneral managerVice presidentPatented medicines pricing review boardInternational gmbh